111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
安罗替尼或贝伐珠单抗联合紫杉烷/卡培他滨治疗 HER-2 阴性转移性乳腺癌二线或后续治疗：一项回顾性队列研究
Authors Xiang J , Sun P, Liu Z, Zhang Q, Song L, Liu J
Received 20 June 2025
Accepted for publication 26 November 2025
Published 8 December 2025 Volume 2025:19 Pages 10871—10883
DOI https://doi.org/10.2147/DDDT.S548425
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Professor Anastasios Lymperopoulos
Jinyu Xiang,1,* Ping Sun,1,* Zeyu Liu,1,* Qingyu Zhang,1 Lei Song,2 Jiannan Liu1
1Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, People’s Republic of China; 2Departments of Geriatric Medicine, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiannan Liu, Email Liujiannansun2013@163.com Lei Song, Email 372042212@qq.com
Background: Anlotinib and bevacizumab have demonstrated efficacy in treating HER-2 (human epidermal growth factor receptor 2)-negative metastatic breast cancer (MBC), yet no comparative studies have been conducted to access their effectiveness in MBC patients. Accordingly, this study aimed to evaluate the safety and effectiveness of anlotinib versus bevacizumab when combined with taxane/capecitabine for second-line or subsequent treatment of HER-2-negative MBC.
Methods: Patients with pathologically confirmed HER-2-negative MBC that underwent second-line or subsequent treatment of anlotinib or bevacizumab plus taxane/capecitabine between April 2020 and October 2021 were retrospectively reviewed. Outcomes including the objective response rates (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were analyzed.
Results: A total of 130 patients were included for this study, with 67 in the anlotinib + chemotherapy group and 63 in the bevacizumab + chemotherapy group. The ORRs were 40.30% for the anlotinib + chemotherapy group and 30.16% for the bevacizumab + chemotherapy group (P = 0.27), while the DCRs were 86.57% and 69.84%, respectively (P = 0.03). Patients in the anlotinib + chemotherapy group showed significantly longer median PFS and OS compared to the bevacizumab + chemotherapy group (mPFS: 8.57 vs 5.90 months, HR 0.55 [95% CI 0.36– 0.85], P = 0.04; mOS: 22.76 vs 16.50 months, HR 0.63[95% CI 0.43– 0.93], P = 0.02). The most common treatment-related adverse events (TRAE) were grade 1/2 alopecia, peripheral neuropathy, hypertension, and granulocytopenia, with both groups exhibiting tolerable TRAE profiles.
Conclusion: In this retrospective analysis, anlotinib combined with taxane/capecitabine demonstrated a manageable safety profile. This regimen was associated with improved DCR, PFS, and OS compared to bevacizumab plus chemotherapy in patients with HER2-negative MBC. These findings suggest that anlotinib may represent a promising therapeutic option for patients for whom ADC drugs are inaccessible or unsuitable; however, further prospective, randomized studies are warranted to confirm.
Keywords: anlotinib, breast cancer, angiogenesis, taxane, capecitabine
1Departments of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, People’s Republic of China; 2Departments of Geriatric Medicine, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, 264000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Jiannan Liu, Email Liujiannansun2013@163.com Lei Song, Email 372042212@qq.com
Background: Anlotinib and bevacizumab have demonstrated efficacy in treating HER-2 (human epidermal growth factor receptor 2)-negative metastatic breast cancer (MBC), yet no comparative studies have been conducted to access their effectiveness in MBC patients. Accordingly, this study aimed to evaluate the safety and effectiveness of anlotinib versus bevacizumab when combined with taxane/capecitabine for second-line or subsequent treatment of HER-2-negative MBC.
Methods: Patients with pathologically confirmed HER-2-negative MBC that underwent second-line or subsequent treatment of anlotinib or bevacizumab plus taxane/capecitabine between April 2020 and October 2021 were retrospectively reviewed. Outcomes including the objective response rates (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were analyzed.
Results: A total of 130 patients were included for this study, with 67 in the anlotinib + chemotherapy group and 63 in the bevacizumab + chemotherapy group. The ORRs were 40.30% for the anlotinib + chemotherapy group and 30.16% for the bevacizumab + chemotherapy group (P = 0.27), while the DCRs were 86.57% and 69.84%, respectively (P = 0.03). Patients in the anlotinib + chemotherapy group showed significantly longer median PFS and OS compared to the bevacizumab + chemotherapy group (mPFS: 8.57 vs 5.90 months, HR 0.55 [95% CI 0.36– 0.85], P = 0.04; mOS: 22.76 vs 16.50 months, HR 0.63[95% CI 0.43– 0.93], P = 0.02). The most common treatment-related adverse events (TRAE) were grade 1/2 alopecia, peripheral neuropathy, hypertension, and granulocytopenia, with both groups exhibiting tolerable TRAE profiles.
Conclusion: In this retrospective analysis, anlotinib combined with taxane/capecitabine demonstrated a manageable safety profile. This regimen was associated with improved DCR, PFS, and OS compared to bevacizumab plus chemotherapy in patients with HER2-negative MBC. These findings suggest that anlotinib may represent a promising therapeutic option for patients for whom ADC drugs are inaccessible or unsuitable; however, further prospective, randomized studies are warranted to confirm.
Keywords: anlotinib, breast cancer, angiogenesis, taxane, capecitabine